Skip to content

Safety and efficacy analysis of apatinib combined with oxaliplatin and capecitabine in neoadjuvant chemotherapy for locally advanced gastric cancer

Safety and efficacy analysis of apatinib combined with oxaliplatin and capecitabine in neoadjuvant chemotherapy for locally advanced gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062090
Enrollment
Unknown
Registered
2022-07-21
Start date
2022-07-20
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric

Interventions

single: neoadjuvant chemotherapy

Sponsors

The First Affiliated Hospital of USTC WEST district
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 75; 2. Gastric adenocarcinoma confirmed by histological or cytological pathology; 3. No surgery or chemotherapy was performed before diagnosis; 4. Diagnosis of locally advanced gastric cancer by imaging (CT) or laparoscopic exploration, cT3N+M0 or cT4NxM0; 5. ECOG (Eastern Cooperative Oncology Group) score 0-1; 6. Normal liver function, kidney function and bone marrow function; 7. Have at least one measurable lesion.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Previous history of malignant tumor; 3. Malignant tumors of other tissues except gastric cancer were found in the same period; 4. Known allergies to drugs used in the regimen, such as apatinib, oxaliplatin, capecitabine; 5. Known tendency of gastrointestinal bleeding; 6. Abnormal coagulation function; 7. Uncontrolled hypertension; 8. Previous history of myocardial infarction.

Design outcomes

Primary

MeasureTime frame
pathologic response rate;

Secondary

MeasureTime frame
objective response rate;disease control rate;margin free resection rate;downstaging;adverse event;

Countries

China

Contacts

Public ContactChen Xi
chenxivascular@yeah.net+86 13866191949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026